Pfizer Caduet Sell-In Is $28 Mil.; Is Streak Of Weak Launches Ending?
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer posts $11 bil. in pharma sales during first quarter, but few recent launches (other than Bextra) are significant contributors. Inspra is off to a slow start, though Pfizer maintains prescriptions are growing "steadily."